Treatment with ABT-263 (navitoclax), a small molecule inhibitor of BCL-2/BCL-xL, was effective in killing HNSCC cells at high doses, but had limited additive effect in combination with radiation or cisplatin. This evidence concerns the gene BCL2 and head and neck squamous cell carcinoma.